B-9100 ml

B-9 100 ml is indicated for the treatment of Folic-acid deficiency Megaloblastic anemia Anemias of nutritional origins, pregnancy, infancy, or childhood.

Drugs for Megaloblastic Anemia, Vitamin-B preparations

B-9 100 ml is essential for the production of certain coenzymes in many metabolic systems such as purine and pyrimidine synthesis. It is also essential in the synthesis and maintenance of nucleoprotein in erythropoesis. It also promotes WBC and platelet production in folate-deficiency anaemia.

Adults: Initially, 5 mg daily for 4 months. Maintenance: 5 mg every 1-7 days, depending on the underlying disease.

Children:

• Up to 1 year: 500 mcg/kg daily.
• Over 1 year: Same as the adult dose.
   

May be taken with or without food.

None has been reported.

B-9 100 ml is contraindicated in patients who have shown previous intolerance to the drug.

B-9 100 ml is generally well tolerated. Gastro-intestinal disturbances may occur. Hypersensitivity reactions have been reported rarely.

Pregnancy Category A. Adequate and well-controlled human studies have not shown any risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

It should be used with caution in patients who may have folate-dependent tumors. It should never be given alone or in conjunction with inadequate amounts of vitamin B12 for the treatment of undiagnosed megaloblastic anemia. Although B-9 100 ml may produce a hematopoietic response in patients with megaloblastic anemia due to vitamin B12 deficiency, it should not be administered alone in vitamin B12 deficiency states, as it may precipitate the onset of subacute combined degeneration of the cord. In elderly individuals, a cobalamin absorption test should be conducted before long-term folate use. No harmful results have been observed from short courses of folate.

Store below 30°C in a dry place, away from light. Keep out of the reach of children.

Drugs for Megaloblastic Anemia, Vitamin-B preparations

B-9 100 ml, although biochemically inactive, undergoes conversion to tetrahydrofolic-acid and methyltetrahydrofolate through the action of dihydrofolate reductase (DHFR). These folic-acid derivatives are transported into cells via receptor-mediated endocytosis, where they play a crucial role in maintaining normal erythropoiesis, synthesizing purine and thymidylate nucleic acids, facilitating amino acid interconversion, methylating tRNA, and producing and utilizing formate. In the presence of vitamin B12 as a cofactor, B-9 100 ml can effectively reduce elevated homocysteine levels by remethylating homocysteine into methionine through methionine synthetase.